EPO and anemia (phenotype): It should be noted that intensive treatment of anemia especially with erythropoietin-stimulating agents to target the serum Hb levels of > 12 g/dL may disrupt cardiovascular safety.49 Furthermore, high levels of ferritin and hyperkalemia due to the administration of RBC could increase the risk of infection, hospitalization, and cardiovascular events.13